Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

BUY
$3.22 - $6.27 $252,863 - $492,376
78,529 New
78,529 $492,000
Q4 2019

Jan 29, 2020

SELL
$1.33 - $5.93 $104,443 - $465,676
-78,529 Closed
0 $0
Q3 2018

Oct 26, 2018

BUY
$10.88 - $14.52 $854,395 - $1.14 Million
78,529 New
78,529 $870,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Conning Inc. Portfolio

Follow Conning Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conning Inc. with notifications on news.